171 related articles for article (PubMed ID: 19678796)
1. Discontinued drugs in 2008: endocrine and metabolic.
Colca JR
Expert Opin Investig Drugs; 2009 Sep; 18(9):1243-55. PubMed ID: 19678796
[TBL] [Abstract][Full Text] [Related]
2. Discontinued drugs 2011: endocrine and metabolic.
Colca JR
Expert Opin Investig Drugs; 2012 Nov; 21(11):1619-24. PubMed ID: 22917013
[TBL] [Abstract][Full Text] [Related]
3. Discontinued drugs in 2012: endocrine and metabolic.
Colca JR
Expert Opin Investig Drugs; 2013 Oct; 22(10):1305-13. PubMed ID: 23961717
[TBL] [Abstract][Full Text] [Related]
4. Discontinued drugs in 2005: endocrine and metabolic.
Colca JR
Expert Opin Investig Drugs; 2007 Feb; 16(2):129-36. PubMed ID: 17243934
[TBL] [Abstract][Full Text] [Related]
5. Discontinued drugs in 2006: renal, endocrine and metabolic drugs.
Colca JR
Expert Opin Investig Drugs; 2007 Oct; 16(10):1517-23. PubMed ID: 17922617
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
Xu J
IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
[No Abstract] [Full Text] [Related]
7. Discontinued drugs in 2005: cardiovascular drugs.
Suckling K
Expert Opin Investig Drugs; 2006 Nov; 15(11):1299-308. PubMed ID: 17040192
[TBL] [Abstract][Full Text] [Related]
8. [Indications for corticotherapy in endocrine and metabolic pathology].
Baquet R
Maroc Med; 1969; 49(527):522-3. PubMed ID: 5398381
[No Abstract] [Full Text] [Related]
9. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
10. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis.
Antoniu SA
Expert Opin Investig Drugs; 2012 Nov; 21(11):1607-18. PubMed ID: 22839355
[TBL] [Abstract][Full Text] [Related]
11. Discontinued drug therapies to treat diabetes in 2014.
Colca JR
Expert Opin Investig Drugs; 2015; 24(9):1241-5. PubMed ID: 26083770
[TBL] [Abstract][Full Text] [Related]
12. Endocrine emergencies.
Daggett P
Br J Hosp Med; 1979 Jan; 21(1):38-44. PubMed ID: 435667
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Diseases Drug Discovery World Summit.
Liu G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):577-82. PubMed ID: 14662006
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological chaperones: potential treatment for conformational diseases.
Bernier V; Lagacé M; Bichet DG; Bouvier M
Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
[TBL] [Abstract][Full Text] [Related]
15. Discontinued drugs in 2006: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2008 Mar; 17(3):269-83. PubMed ID: 18321227
[TBL] [Abstract][Full Text] [Related]
16. Discontinued cardiovascular drugs in 2013 and 2014.
Zhao HP; Xiang BR
Expert Opin Investig Drugs; 2015; 24(8):1083-92. PubMed ID: 26162717
[TBL] [Abstract][Full Text] [Related]
17. ZD-6126 AstraZeneca.
Soltau J; Drevs J
IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Diseases Drug Discovery World Summit--SRI conference. 28-29 July 2003 San Diego, CA, USA.
Knittel T
IDrugs; 2003 Sep; 6(9):845-9. PubMed ID: 14565169
[No Abstract] [Full Text] [Related]
19. Discontinued cardiovascular drugs in 2015.
Zhao HP; Dai Y; Xiang BR
Expert Opin Investig Drugs; 2016 Sep; 25(9):1093-101. PubMed ID: 27427204
[TBL] [Abstract][Full Text] [Related]
20. [On the therapeutic use of vitamin E in clinical medicine: motivations and prospects].
Butturini U
Acta Vitaminol Enzymol; 1977; 31(1-5):125-42. PubMed ID: 580682
[No Abstract] [Full Text] [Related]
[Next] [New Search]
